Ribozymes have enormous potential as antiviral agents. We have previously reported that a hairpin ribozyme expressed under the control of the 3-actin promoter that cleaves human Immunodeficiency virus type 1 (HIV-1) 
RNA in the leader sequence can inhibit HIV-1 (pHXB2gpt) expression. For such a ribozyme in a retroviral vector delivery system to be useful in gene therapy for the treatment of HIV-1 infection, it must be able to inhibit the expression of multiple HIV-1 strains. We have now cloned this ribozyme into various regular expression vectors (including retroviral vectors) by using various gene expression control strategies. Here we show by transient tansection that inhibition ofexpression ofdiverse shtains of HIV-1 can be achieved by this ribozyme expressed in the proper vectors. These data further support the potential of this hairpin ribozyme as a therapeutic agent for HIV-1.
Ribozyme technology has emerged as a powerful extension of the antisense approach to inhibition of gene expression (1) . Intracellular expression of hammerhead-type ribozymes directed against human immunodeficiency virus type 1 (HIV-1) RNA has been extensively studied and shown to confer resistance to HIV-1 infection (2) (3) (4) . A hairpin ribozyme was originally discovered (7) in the negative-strand satellite RNA of the tobacco ringspot virus. This small RNA genome utilizes cis-cleaving ribozymes during rolling-circle replication (5) (6) (7) (8) (9) (10) . We have described (11) an engineered form ofthis hairpin ribozyme that was designed to cleave the 5' leader sequence of HIV-1 HXB2 clone mRNA at position +111/112 from the cap site. In vitro study demonstrated that one ribozyme molecule can cleave multiple target molecules (unpublished result). Expression of this hairpin ribozyme under the control of the /-actin promoter inhibited HIV-1 (HXB2) expression and Tat activity.
One important parameter to ensure the efficacy of the ribozyme against HIV infection is high intracellular expression. This (11) plasmids (which contain the active and disabled ribozymes, respectively) upstream of the ribozyme coding sequence at EcoRI-BamHI sites (Fig. 1) . The resultant plasmids containing the pol III promoters were digested with Mlu I and Pst I to remove the autocatalytic cassette (11) and replace it with pol III termination sequences (17 'To whom reprint requests should be addressed. Fig. 1 ). The retroviral vector with an internal 3-actin promoter was constructed using the same vector, with an EcoRI-BamHI insert taken from p3-HR (11) .
The hairpin autocatalytic cassette (11) 
RESULTS
Effects of the Ribozyme Driven by pol m Promoters on HIV-1 Expression. We cloned the HIV-1 5'-leader-sequencespecific ribozyme gene into mammalian expression vectors downstream of the human tRNAval promoter and the adenovirus VA] promoter and upstream of the pol III termination signal (ref. 18 and Fig. 1 ). The expression of the ribozyme in HeLa cells transfected with these plasmids was determined by RNA dot blot analysis. When compared with human f-actin promoter (pol II)-controlled expression (10), the expression of the ribozyme driven by a pol III promoter was 88% higher (data not shown).
To determine the effectiveness of ribozyme-mediated inhibition of HIV expression in a transient assay, an effector plasmid (pHXB2gpt), a reporter plasmid (pC15CAT) (19) , and the ribozyme-containing plasmids (pJT-HR and pJV-HR) or pUC19 as the control were cotransfected into HeLa cells by the calcium phosphate method as described (11) . For comparison, the same ribozyme driven by the ,B-actin promoter (11) was used in parallel. Cell lysates were subjected to chloramphenicol acetyltransferase assay, and the levels of HIV-1 p24 antigen (gag gene product) in the culture supernatant were analyzed by ELISA. The results obtained were graphed as the relative percentage of control value (100lo) ( Fig. 2 A and B) . The HIV-1 ribozyme expressed by pol III promoters inhibited HIV-1 expression significantly (overall 70-95%). In the assay for Tat protein activity ( Fig. 2A) , the ribozyme directed by the tRNAval promoter yielded >10lo greater inhibition than the ribozyme directed by 3-actin promoter. For p24 expression (Fig. 2B) , ribozymes directed by both pol III promoters yielded 15-25% more inhibition than the ,B-actin promoter-directed ribozyme. As described (11), the effect of the ribozyme-containing pol III promoter plasmids for the inhibition of HIV-1 expression was DNAdose-dependent (data not shown).
Cleavage and Target Specificity of the Ribozyme. Our previous study showed that inhibition by the ribozyme driven by the ,B-actin promoter functioned primarily as a catalytic and not an antisense molecule and that its action was dependent on the presence of a target sequence (11) . We have now verified a similar function and specificity for the pol IIIpromoter-driven ribozymes. To determine the contribution of the catalytic activity vs. the antisense activity to the inhibition ofHIV-1 expression, a disabled ribozyme (11) with three point mutations (AAA --UGC, positions 22-24) was constructed in pol III promoter-containing plasmids. These mutations rendered the ribozyme inactive but had no effect on its binding to target RNA (11) . Wild-type and disabled ribozymes were expressed at the same levels in transfected cells but the disabled ribozyme yielded only =10% inhibition of HIV-1 expression (data not shown). Therefore, the inhibition of HIV-1 replication and expression observed is probably contributed mainly by the catalytic property of the ribozyme and not its antisense features. When We further determined whether the reduced expression of HIV-1 proteins directly resulted from a reduced amount of HIV-1 mRNA. Equal amounts of total RNA from HeLa cells transfected with pHXB2gpt/pJV-HR and pHXB2gpt/pUC19 at a weight (pg) ratio of 1:10 were subjected to dot blot analysis with HIV-1-specific DNA. The result shown in Fig.  2C indicates that the presence of the ribozyme reduced HIV-1 transcripts by 71%. The level of viral protein p24 inhibition observed in vivo (80-90%, Fig. 2B ) was higher than the levels observed via RNA dot blot analysis (71%, Fig. 2C ), possibly due to the fact that some viral mRNA is only partially degraded and is still detectable by dot blot but not translatable into proteins.
The Leader-Sequence Ribozyme Inhibits Diverse HIV-1
Strains. A necessary feature of any effective therapeutic agent against AIDS will be its ability to inhibit various HIV-1 strains. We addressed this important issue by using different retroviral vectors containing the ribozyme (Fig. 1) to cotransfect with DNA constructs from a variety of HIV-1 strains. Three strains, MN, SF-2, and Eli, were chosen that exhibit various genetic distances from HXB2, with Eli (a Zairean strain) being the most distant. Interestingly, the leader sequence targeted by the ribozyme under study (TGCCCGTC-TGTTGTGT) is completely conserved among known HIV-1 strains, including the Zairean strain Eli, with the exception of that ofMN, which shows a 1-base mutation [(ower case type) TGCCCGTCTGTTaTGT] (20) . As seen in Fig. 3A , all three retroviral vectors in which the ribozyme gene is driven by the internal promoters (Fig. 1) show significant inhibition of SF-2 expression (compare pMJT, pMJV, and pMHR to the control bar pLRNL-2). These three internal promoters include our previously reported pol II promoter-driven (-actin reported here. On the other hand, the retroviral vector pMJF-1 in which the ribozyme gene is driven directly by Moloney murine leukemia virus LTR (Fig. 1) did not inhibit HIV-1 expression (Fig. 3A , compare bars pMJF-1 and pLRNL-2). To determine whether the inability of pMJF-1 to inhibit SF-2 is due to the lack of expression of the ribozyme in this vector, RNA dot blot analysis was carried out (Fig.  3B) . Expression of ribozyme sequences was detected in all retroviral vectors carrying the ribozyme gene including pMJF-1. In contrast, the vector alone (bar pLRNL-2) produced no ribozyme. In fact, pMJF-1, which did not inhibit the HIV-1 expression, is one of the high-expression vectors. A possible explanation for the inability of this vector to inhibit virus expression is that the ribozyme cloning site is several hundred base pairs away from the transcription initiation point. The extra long arm attached at the 5' end of the ribozyme may interact with cellular nucleic acids or proteins, which affect its accessibility to the substrates.
The effect of pMJT, pMJV, and pMHR on Eli and MN was then investigated. As shown in Fig. 4A, a similar 4A). Slightly less but still significant inhibition was observed for the MN strain (Fig. 4B) , suggesting that the single-base substitution in target sequence has some effect on ribozyme activity.
DISCUSSION
We have been interested in developing ribozymes as antiviral agents in gene therapy for the treatment of HIV-1 infection. The use of catalytic RNA provides a unique approach to the reduction and perhaps elimination of HIV-specific RNA (incoming HIV genome and de novo-synthesized transcripts) and may interfere with more than one step of the infection cycle. We have shown (11) the effect of a hairpin ribozyme driven by the 1-actin promoter on HIV expression. In exploring more efficient systems for high and ubiquitous expression ofthe ribozyme, we have expressed the ribozyme under the control of a pol III promoter (Fig. 1 ) and determined its effect on HIV-1 replication and expression. The current study shows that the ribozyme in pol III expression cassette can inhibit HIV-1 expression up to 95% (p24) by transient transfection assay (Fig. 2B, pJT-HR) . The inhibition of gag gene-encoded p24 concomitant with a substantial reduction in tat activity suggests that the ribozyme can affect HIV-1 replication. Furthermore, HIV-1 RNAs were degraded with high specificity (Fig. 2C) .
The use of the 5' leader sequence of HIV-1 as the target is desirable since it would inhibit expression of both early and late viral gene products due to its presence in all HIV-1 RNA transcripts. By cleaving at this site, the ribozyme renders the RNA capless, so that it is poorly translated and presumably more quickly degraded. Another important consideration in the choice of this 5' leader sequence of HIV-1 as the target is its conservation among most of the HIV-1 isolates. As an effective therapeutic agent, it is essential for the ribozyme to be able to target a variety of HIV-1 strains. We tested several diverse HIV-1 strains in addition to HXB2, including SF-2, MN, and Eli. SF-2 and Eli contain the same target sequence, but the overall genomic sequences are quite diverse, especially Eli, which is a Zairean virus. Therefore, the accessibility of the same target sequence embedded in divergent genomes will be important to address. Of all the available HIV-1 sequences, only MN contains one nucleotide substitution in the target sequence (20) . Although in vitro studies suggested that such a conservative G -* A substitution at that position may be tolerated in a ribozyme-substrate interaction (21) , one cannot predict whether such is also the case in vivo.
In designing experiments to address the various issues of strain diversity, we utilized ribozymes expressed in retroviral vector constructs. Since retroviral vectors are still the preferred vehicles for gene delivery to human hematopoietic cells, including stem cells, these constructs were prepared as a further step toward gene therapy. The results showed that SF-2 and Eli were efficiently inhibited by the ribozymes (70-95%, Figs. 3A and 4A) expressed from internal promoters in the Moloney murine leukemia virus-based vectors, and MN was inhibited only to a slightly lesser extent (50-70%, Fig. 4B ). These results are encouraging to our long-term efforts in continuously refining the expression and delivery of hairpin ribozymes as a gene-therapy approach to the treatment of HIV-1 infection. However, to ensure efficacy of the hairpin ribozyme, we have developed the second HIV-1 ribozyme that targets the HIV-1 pol sequence (bp 2490-2504 in the HXB2 clone). Attacking multiple targets should yield greater inhibition as well as safeguard against the generation of escape mutants.
